LONDON, April 10, 2014 /PRNewswire/ --
The trading session on Wednesday, April
09, 2014 ended on a positive note as the Dow Jones
Industrial Average finished at 16,437.18, up 1.11% and the NASDAQ
Composite closed at 4,183.90, up 1.72%. The S&P 500 finished
the session 1.09% higher at 1,872.18. The gains were broad based as
eight out of ten sectors posted gains. The S&P 500 Health Care
Sector Index finished the day 2.11% higher at 673.27, and the same
has gained 2.86% in the previous three months. Investor-Edge has
initiated coverage on the following equities: Investor-Edge has
initiated coverage on the following equities: AVANIR
Pharmaceuticals Inc. (NASDAQ: AVNR), Zoetis Inc. (NYSE: ZTS), Salix
Pharmaceuticals Ltd (NASDAQ: SLXP) and Jazz Pharmaceuticals PLC
(NASDAQ: JAZZ). Free technical research on AVNR, ZTS, SLXP and JAZZ
can be downloaded upon signing up at:
http://www.investor-edge.com/1006-register
Shares in AVANIR Pharmaceuticals Inc. reported a trading volume
of 1.74 million shares, as compared with its three months average
volume of 2.28 million shares. The stock ended the day at an
intra-day high of $3.87, up 8.40%,
and at an intraday range of $3.59 and
$3.87. AVANIR Pharmaceuticals Inc.'s
shares have gained 11.85% in the previous three trading sessions
and 15.18% on YTD basis, while the same has declined 13.42% in the
last one month. The stock is trading below its 50-day and 200-day
moving averages of $3.90 and
$4.22, respectively. Moreover, the
stock has a Relative Strength Index (RSI) of 42.29. Sign up today
to read free research on AVNR at:
http://www.investor-edge.com/1006-AVNR-10Apr2014.pdf
Zoetis Inc.'s stock finished the session 0.31% lower at
$29.06. A total of 3.63 million
shares were traded, which is below its three months average volume
of 4.97 million shares. The stock fluctuated between $28.77 and $29.22 during the session. The
company's shares traded at a PE ratio of 21.15. Zoetis Inc.'s stock
has fallen by 0.89% in the previous three trading sessions, 4.97%
in the last one month and 11.10% on YTD basis. The stock is trading
below its 50-day and 200-day moving averages of $29.96 and $30.98,
respectively. Further, the stock has an RSI of 42.88. Sign up today
to read free research on ZTS at:
http://www.investor-edge.com/1006-ZTS-10Apr2014.pdf
On Wednesday, shares in Salix Pharmaceuticals Ltd gained 3.71%
to close the day at $105.76. The
stock recorded a trading volume of 0.98 million shares as compared
with its three months average volume of 1.10 million shares. The
stock oscillated between $101.83 and
$105.99 during the trading session. Shares of the company
traded at a PE ratio of 48.23. Salix Pharmaceuticals Ltd's shares
have advanced 3.46% in the previous three trading sessions and
17.59% on YTD basis, while the same has declined 3.73% in the last
one month. The stock is trading above its 50-day and 200-day moving
averages of $105.12 and $83.55, respectively. Moreover, the stock has an
RSI of 43.74. Sign up today to read free research on SLXP at:
http://www.investor-edge.com/1006-SLXP-10Apr2014.pdf
Jazz Pharmaceuticals PLC's stock recorded a trading volume of
1.32 million shares, as compared with its three months average
volume of 1.27 million shares. The stock ended the day at
$136.91, up 5.24%, after vacillating
between $130.86 and $136.97. The
company's shares traded at a PE ratio of 35.52. Jazz
Pharmaceuticals PLC's shares have gained 7.97% in the previous
three trading sessions and 8.18% on YTD basis, while the same has
fallen by 11.81% in the last one month. The company's stock is
trading below its 50-day moving average. Jazz Pharmaceuticals PLC's
50-day moving average of $151.15 is
above its 200-day moving average of $110.51. Furthermore, shares of the company have
an RSI of 37.72. Sign up today to read free research on JAZZ
at:
http://www.investor-edge.com/1006-JAZZ-10Apr2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and
our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Namrata
Maheshwari, a CFA charterholder. However, we are only human
and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by
our team, or wish to learn more about our services, please contact
us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Namrata Maheshwari, CFA, has only
reviewed the information provided by Investor-edge in this article
or report according to the Procedures outlined by Investor-edge.
Investor-edge is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the
articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://www.investor-edge.com/
SOURCE Investor-Edge